Royal Bank of Canada Grows Position in Danaher Corporation $DHR

Key Points

• Royal Bank of Canada increased its stake in Danaher Corporation by 0.6%, owning nearly 2.96 million shares valued at approximately $607 million as of their latest SEC filing.
• Several hedge funds, including ICW Investment Advisors and Armistice Capital, have also adjusted their positions in Danaher, showcasing significant investment interest in the company.
• Analysts have generally given Danaher a consensus rating of "Moderate Buy", with an average price target of $247.61, indicating optimism for the company's stock performance.

Royal Bank of Canada raised its stake in Danaher Corporation (NYSE:DHR - Free Report) by 0.6% in the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 2,964,951 shares of the conglomerate's stock after purchasing an additional 16,955 shares during the period. Royal Bank of Canada owned 0.41% of Danaher worth $607,817,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Coastal Bridge Advisors LLC increased its stake in shares of Danaher by 4.8% in the 4th quarter. Coastal Bridge Advisors LLC now owns 1,099 shares of the conglomerate's stock worth $252,000 after acquiring an additional 50 shares in the last quarter. Hills Bank & Trust Co increased its stake in shares of Danaher by 0.3% in the 1st quarter. Hills Bank & Trust Co now owns 18,015 shares of the conglomerate's stock worth $3,693,000 after acquiring an additional 53 shares in the last quarter. Sageworth Trust Co increased its stake in Danaher by 2.3% during the 1st quarter. Sageworth Trust Co now owns 2,404 shares of the conglomerate's stock valued at $493,000 after purchasing an additional 54 shares in the last quarter. 1834 Investment Advisors Co. increased its stake in Danaher by 3.3% during the 1st quarter. 1834 Investment Advisors Co. now owns 1,666 shares of the conglomerate's stock valued at $342,000 after purchasing an additional 54 shares in the last quarter. Finally, Rakuten Securities Inc. increased its stake in Danaher by 33.3% during the 1st quarter. Rakuten Securities Inc. now owns 224 shares of the conglomerate's stock valued at $46,000 after purchasing an additional 56 shares in the last quarter. 79.05% of the stock is owned by institutional investors.

Insider Activity at Danaher

In other news, Director Teri List sold 2,778 shares of the business's stock in a transaction on Friday, August 22nd. The shares were sold at an average price of $211.06, for a total value of $586,324.68. Following the transaction, the director owned 20,751 shares of the company's stock, valued at approximately $4,379,706.06. The trade was a 11.81% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Company insiders own 11.20% of the company's stock.

Danaher Stock Performance

Shares of DHR traded down $0.47 on Thursday, reaching $198.97. The company's stock had a trading volume of 3,627,515 shares, compared to its average volume of 4,153,999. The company has a debt-to-equity ratio of 0.32, a current ratio of 1.62 and a quick ratio of 1.22. The stock has a market capitalization of $142.47 billion, a P/E ratio of 42.33, a PEG ratio of 2.87 and a beta of 0.75. The stock's 50 day simple moving average is $201.94 and its two-hundred day simple moving average is $199.49. Danaher Corporation has a 12-month low of $171.00 and a 12-month high of $279.90.

Danaher (NYSE:DHR - Get Free Report) last issued its quarterly earnings results on Tuesday, July 22nd. The conglomerate reported $1.80 earnings per share for the quarter, beating the consensus estimate of $1.64 by $0.16. Danaher had a net margin of 14.21% and a return on equity of 10.70%. The business had revenue of $5.94 billion for the quarter, compared to the consensus estimate of $5.83 billion. During the same quarter in the previous year, the firm earned $1.72 earnings per share. The company's revenue for the quarter was up 3.4% on a year-over-year basis. Danaher has set its FY 2025 guidance at 7.700-7.800 EPS. Research analysts forecast that Danaher Corporation will post 7.63 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of research firms have weighed in on DHR. Scotiabank upgraded shares of Danaher from a "sector perform" rating to a "sector outperform" rating and set a $275.00 price objective for the company in a research note on Friday, July 11th. Robert W. Baird raised their price objective on shares of Danaher from $225.00 to $226.00 and gave the company an "outperform" rating in a research note on Friday, July 18th. Wall Street Zen upgraded shares of Danaher from a "hold" rating to a "buy" rating in a research note on Friday, June 27th. Evercore ISI reduced their price target on shares of Danaher from $230.00 to $226.00 and set an "outperform" rating for the company in a research note on Tuesday, July 8th. Finally, UBS Group reduced their price target on shares of Danaher from $240.00 to $225.00 and set a "buy" rating for the company in a research note on Wednesday, July 23rd. Seventeen analysts have rated the stock with a Buy rating and three have given a Hold rating to the company's stock. According to MarketBeat.com, Danaher currently has a consensus rating of "Moderate Buy" and an average target price of $246.35.

About Danaher

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.